One Up, One Down: Morgan Stanley Flips Merck, Bristol-Myers Ratings
April 17, 2018 at 14:16 PM EDT
Merck & Co., Inc. (NYSE: MRK)’s Keytruda returned better-than-expected results in the Keynote-189 lung study — a feat ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|